TRANSPOSON-BASED MODIFICATIONS OF IMMUNE CELLS
The present invention provides methods and compositions for stable genetic modification of immune cells. The genetic modifications can be used to produce immune cells for therapeutic or diagnostic purposes.
1 .- 59 . (canceled)
60 . A polynucleotide, comprising:
a first nucleotide sequence encoding a chimeric antigen receptor comprising an extracellular domain that specifically binds to a CD19 antigen; and
a second nucleotide sequence encoding either an apoptosis inhibitor selected from the group consisting of SEQ ID NOs: 237, 238, and 271 or an activating mutant consisting of SEQ ID NO. 251.
61 . The polynucleotide of claim 60 , wherein the second nucleotide sequence encodes an apoptosis inhibitor consisting of SEQ ID NO: 237.
62 . The polynucleotide of claim 60 , wherein the second nucleotide sequence encodes an apoptosis inhibitor consisting of SEQ ID NO: 238.
63 . The polynucleotide of claim 60 , wherein the second nucleotide sequence encodes an activating mutant consisting of SEQ ID NO. 251.
64 . The polynucleotide of claim 60 , further comprising a transposon.
65 . The polynucleotide of claim 64 , wherein:
(A) the second nucleotide sequence is operably linked to a heterologous promoter; and
(B) the polynucleotide is flanked by a pair of transposon ends.
66 . The polynucleotide of claim 60 , further comprising a lentiviral vector.
67 . A T cell expressing a polynucleotide, the polynucleotide comprising:
a first nucleotide sequence encoding a chimeric antigen receptor comprising an extracellular domain that specifically binds to a CD19 antigen; and
a second nucleotide sequence encoding either an apoptosis inhibitor selected from the group consisting of SEQ ID NOs: 237, 238, and 271 or an activating mutant consisting of SEQ ID NO. 251.
68 . The T cell of claim 67 , wherein the second nucleotide sequence encodes an apoptosis inhibitor consisting of SEQ ID NO: 237.
69 . The T cell of claim 67 , wherein the second nucleotide sequence encodes an apoptosis inhibitor consisting of SEQ ID NO: 238.
70 . The T cell of claim 67 , wherein the second nucleotide sequence encodes an activating mutant consisting of SEQ ID NO. 251.
71 . The T cell of claim 67 , wherein:
a persistence of the T cell is increased relative to a persistence of a T cell that does not comprise the first and second nucleotide sequences; and/or
a proliferation rate of the T cell is increased relative to a proliferation rate of a T cell that does not comprise the first and second nucleotide sequences.
72 . The T cell of claim 67 , wherein the polynucleotide is integrated into the genome of the T cell.
73 . The T cell of claim 67 for use in the treatment of cancer.
74 . The T cell of claim 67 for use in the treatment of a B cell malignancy.
75 . A kit, comprising:
(A) a polynucleotide, comprising:
(1) a first nucleotide sequence encoding a chimeric antigen receptor comprising an extracellular domain that specifically binds to a CD19 antigen;
(2) a second nucleotide sequence encoding either an apoptosis inhibitor selected from the group consisting of SEQ ID NOs: 237, 238, and 271 or an activating mutant consisting of SEQ ID NO. 251; and
(3) a transposon; and
(B) a transposase capable of transposing the transposon or a nucleic acid encoding a transposase capable of transposing the transposon.
76 . The kit of claim 75 , wherein the second nucleotide sequence encodes an apoptosis inhibitor consisting of SEQ ID NO: 237.
77 . The kit of claim 75 , wherein the second nucleotide sequence encodes an apoptosis inhibitor consisting of SEQ ID NO: 238.
78 . The kit of claim 75 , wherein the second nucleotide sequence encodes an activating mutant consisting of SEQ ID NO. 251.
79 . The kit of claim 75 , further comprising an anti-hCD19-CD3 bispecific T cell engager.
80 . The kit of claim 75 , wherein, when the kit comprises a nucleic acid encoding the transposase, the nucleic acid encoding the transposase is an mRNA.